Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo

Circulation

Volumn 97, Issue 23, 1998, Pages 2323-2330

  Ferro, Charles J ^a   Spratt, James C ^a   Haynes, William G ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angiotensin II; Endothelin; Human; Natriuretic peptides; Vasoconstriction

Indexed keywords

CANDOXATRIL; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENALAPRIL; PROTEINASE; THIORPHAN;

AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; DRUG EFFECT; FOREARM BLOOD FLOW; HUMAN; MALE; NATRIURESIS; PRIORITY JOURNAL; PROTEINASE INHIBITION; RESISTANCE BLOOD VESSEL; VASOCONSTRICTION;

EID: 0032537519     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.23.2323     Document Type: Article

References (68)

1. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989;3:145-151.
2. Stephenson SL, Kenny AJ. The hydrolysis of α-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987;243:183-187.
3. Lang CC, Motwani JG, Coutie WJR, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor. Clin Sci. 1992;82:619-623.
4. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilantin, C-type natriuretic peptide, and some C-receptor ligands by endopeptidase-24.11. Biochem J. 1993;291:83-88.
5. Skidgel RA, Engelbrecht S, Johnson AR, Erdös EG. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides. 1984;5:769-776.
6. Abassi Z, Golomb E, Keiser HR. Neutral endopeptidase inhibition increases the urinary excretion and plasma levels of endothelin. Metabolism. 1992;41:683-685.
7. Murphy L, Corder R, Mallet A, Turner A. Generation by the phosphoramidon-sensitive peptidases, endopeptidase 24.11 and thermolysin, of endothelin-1 and C-terminal fragment from big endothelin-1. Br J Pharmacol. 1994;113:137-142.
8. Danilewicz JC, Barclay PL, Barnish IT, Brown D, Campbell SF, James K, Samuels GMR, Terret NK, Wythes MJ. UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic. Biochem Biophys Res Commun. 1989;164:58-65.
9. Schwartz JC, Gros C, Lecomte JM, Bralet J. Enkephalinase (EC 3.4.24.11) inhibitors: protection of endogenous ANF against inactivation and potential therapeutic applications. Life Sci. 1990;47:1279-1297.
10. Gros C, Souque A, Schwartz J-C, Duchier J, Cournot A, Baumer P, Lecomte J-M. Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 4.4.24.11) by acetorphan. Proc Natl Acad Sci U S A. 1989;86:7580-7584.
11. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atria] myocardial extract in rats. Life Sci. 1981;28:89-94.
12. Currie MG, Geller DM, Cole BR, Boylan JG, YuSheng W, Holmberg SW, Needleman P. Bioactive cardiac substances: potent vasorelaxant activity in mammalian atria. Science. 1983;221:71-73.
13. Webb DJ, Benjamin N, Allen M, Brown J, O'Flynn M, Cockcroft JR. Vascular responses to local a trial natriuretic peptide infusion in man. Br J Clin Pharmacol. 1988;26:245-251.
14. Brands WM, Freedman RH. Aldosterone and renin inhibition by physiological levels of atrial natriuretic factor. Am J Physiol. 1988;254: R1011-R1016.
15. Atarashi K, Mulrow PJ, Franco-Saenz R, Snajdar R, Rapp J. Inhibition of aldosterone production by an atrial extract. Science. 1984;224:992-994.
16. Struthers AD. Ten years of natriuretic peptide research: a new dawn for their diagnostic and therapeutic use? BMJ. 1994;308:1615-1619.
17. Northridge DB, Jardine AG, Alabaster CT, Barclay PL, Connell JMC, Dargie HJ, Dilly SG, Findlay IN, Lever AF, Samuels GMR. Effects of UK 69 578: a novel atriopeptidase inhibitor. Lancet. 1989;2:591-593.
18. Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H. Prolonged inhibition of endopeptidase EC 24.11 in normal man: renal, endocrine and haemodynamic effects. J Hypertens. 1991;9:955-962.
19. Bevan EG, Connell JMC, Doyle J, Carmichael HA, Davies DL, Lorimer AR, McInnes GT. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens. 1992;10:607-613.
20. Richards M, Espiner E, Frampton C, Ikram H, Yandle T, Sopwith M, Cussans N. Inhibition of endopeptidase 24.11 in humans: renal and endocrine effects. Hypertension. 1990;16:269-276.
21. O'Connell JE, Jardine AG, Davies DL, McQueen J, Connell JMC. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clin Sci. 1993;85:19-26.
22. Ando S, Rahman MA, Butler GC, Senn BL, Floras JS. Comparison of candoxatril and atrial natriuretic factor in healthy men: effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension. 1995;26:1160-1166.
23. Motwani JG, Lang CC, Cramb G, Struthers AD. Natriuretic response to neutral endopeptidase inhibition is blunted by enalapril in healthy men. Hypertension. 1995;25:637-642.
24. Lefrancois P, Clerc G, Duchier J, Lim C, Lecomte JM, Gros C, Schwartz JC. Antihypertensive activity of sinorphan. Lancet. 1990;336:307-308.
25. Sybertz EJ. SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator. Clin Nephrol. 1991;4:187-191.
26. Richards AM, Crozier IG, Kosoglou T, Rallings M, Espiner EA, Nicholls MG, Yandle TG, Ikram H, Frampton C. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension. 1993;22:119-126.
27. Richards AM, Crozier IG, Espiner EA, Yandle TG, Nicholls MG. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in essential hypertension. Hypertension. 1993;22:231-236.
28. Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11:407-416.
29. Tunny TJ, Ziesak MD, Armstrong R, Klemm SA, Stowasser M, Finn WL, Gordon RD. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension. J Hypertens. 1993;11(suppl 5):S222-S223.
30. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens. 1994;7:943-947.
31. Fettner SH, Pai S, Zhu G-R, Kosoglou T, Banfield CR, Batra V. Pharmacokinetic-pharmacodynamic (PK-PD) modeling for a new antihypertensive agent (neutral metallopeptidase inhibitor SCH 42354) in patients with mild to moderate hypertension. Eur J Clin Pharmacol. 1995;48:351-359.
32. Singer DRJ, Markandu ND, Buckley MG, Miller MA, Sagnella GA, MacGregor GA. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension. 1991;18:798-804.
33. O'Connell JE, Jardine AG, Davidson AG, Davidson G, Connell JMC. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens. 1992;10:271-277.
34. Richards AM, Crozier IG, Espiner EA, Ikram H, Yandle TG, Kosoglou T, Railings M. Frampton C. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardiovasc Pharmacol. 1992;20:735-741.
35. Favrat B, Burnier M, Nussberger J, Lecomte JM, Brouard R, Waeber B, Brunner HR. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens. 1995;13:797-804.
36. Kahn JC, Patey M, Dubois-Rande JL, Merlet P, Castaigne A, Lim-Alexandre C, Lecomte JM, Duboc D, Gros C, Schwartz JC. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet. 1990;335:118-119.
37. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet. 1994;344:852-854.
38. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation. 1996;94:2131-2137.
39. Barclay PL, Danilewicz JC, Samuels GMR. Inhibitory properties of UK-69 578 and thiorphan. Lancet. 1990;336:754-755.
40. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension. 1990;16:564-572.
41. Webb DJ. The pharmacology of human blood vessels in vivo. J Vasc Res. 1995;32:2-15.
42. Wiinberg N, Walter-Larson S, Eriksen C, Nielsen PE. An evaluation of semi-automatic blood pressure manometers against intra-arterial blood pressure. J Ambulatory Monitoring. 1988;1:303-309.
43. Plumpton C, Haynes WG, Webb DJ, Davenport AP. Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br J Pharmacol. 1995;116:1821-1828.
44. Millar JA, Leckie BJ, Morton JJ, Jordan J, Tree M. A micro assay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta. 1980;101:5-15.
45. Morton JJ, Webb DJ. Measurement of plasma angiotensin II. Clin Sci. 1985;68:483-484.
46. Richards AM, Tonolo G, McIntyre GD, Leckie BJ, Robertson JIS. Radioimmunoassay for plasma alpha human atrial natriuretic peptide: a comparison of direct and pre-extracted methods. J Hypertens. 1987;5:227-236.
47. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504-509.
48. Rolinski B, Sadri I, Bogner J, Goebel F-D. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res Exp Med. 1994;194:9-24.
49. Kerslake DM. The effect of application of an arterial occlusion cuff to the wrist on the blood flow in the human forearm. J Physiol (Lond). 1949;108:451-457.
50. Matthews JNS, Altman DC, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230-235.
51. Altman D, Bland M. Comparing several groups by analysis of variance. BMJ. 1996;312:1472-1473.
52. McMahon EG, Palomo MA, Moore WM. Phosphoramidon blocks the pressor activity of big endothelin-1 [1-39] and lowers blood pressure in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1989:17(suppl 7):S29-S33.
53. Olins GM, Krieter PA, Trapani AG, Spear KL, Bovy PR. Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial peptides in vitro and in vivo. Mol Cell Endocrinol. 1989;61:201-208.
54. Collier JG, Lorge RE, Robinson BF. Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate on forearm arteries and dorsal hand veins of man. Br J Clin Pharmacol. 1978;5:35-44.
55. Barclay PL, Bennet JA, Samuels GMR, Shepperson NB. The atriopeptidase inhibitor (±) candoxatrilat reduces the clearance of atrial natriuretic factor in both intact and nephrectomized rats: evidence for an extra-renal site of action. Biochem Pharmacol. 1991;41:841-844.
56. Graf K, Koehne P, Gräfe M, Zhang M, Auch-Schwelk W, Fleck E. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension. 1995;26:230-235.
57. Dussaule J-C, Stefanski A, Bea M-L, Ronco P, Ardaillou R. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol. 1993;264:F45-F52.
58. Clarke JG, Benjamin N, Larkin SW, Webb DJ, Davies GJ, Maseri A. Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol. 1989;257:H2033-H2035.
59. Chalmers JP, Wing LMH, West MJ, Bune AJC, Elliott JM, Morris MJ, Cain MD, Graham JR, Southgate DO. Effects of enalapril and hydrochlorothiazide on blood pressure, renin-angiotensin system, and atrial natriuretic factor in essential hypertension: a double blind factorial cross-over study. Aust N Z J Med. 1986;16:475-480.
60. Doorembos CJ, van Brummelen P. The effect of acute ACE inhibition on atrial natriuretic peptide. Br J Clin Pharmacol. 1989;27:243S-247S.
61. Olins GM, Spear KL, Siegel NR, Reinhard EJ, Zurcher-Neely HA. Atrial peptide inactivation by rabbit-kidney brush border membranes. Eur J Biochem. 1987;170:431-434.
62. Uemasu J, Matsumoto H, Kitano M, Kawasaki H. Suppression of plasma endothelin-1 level by α-human atrial natriuretic peptide and angiotensin converting enzyme inhibition in normal men. Life Sci. 1993;53:969-974.
63. Wagner O, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny P, Schneider B, Waldhausl W, Binder B. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
64. A receptors in humans? Trends Pharmacol Sci. 1994;15:9-11.
65. Kentsch M, Otter W, Drummer C. Nötges A, Gerzer R, Müller-Esch G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol. 1996;51:269-272.
66. Monopoli A, Ongini E, Cigola E, Olivetti G. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1992;20:496-504.
67. Kugiyama K, Sugiyama S, Ohgushi M, Matsumura T, Vasue H. Suppression of atherosclerotic changes in cholesterol fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11; NEP). Circulation. 1993;88(suppl I):I-521 Abstract.
68. Gray GA, Webb DJ. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther. 1996;72:109-148.